Ancocare was founded in 2018 by a team of world-leading virologists and former senior reviewers from the U.S. FDA/China CDE. The company is dedicated to developing anti-tumor and various gene therapy drugs, leveraging a globally unique RNA vector technology platform based on the Flavivirus.
Mar 2021
Angel round of financing
Feb 2022
Angel+ round of financing
Sep，2023
Launched Pre-A round financing project
Mar 2021
Angel round of financing
Feb 2022
Angel+ round of financing
Sep，2023
Launched Pre-A round financing project
2018
Dec
Incorporation
2019
Dec
Construction, identification, and production of viral vectors
2020
Mar
Preclinical studies on pharmacology and toxicity
Mar
Completed pharmacodynamic and toxicological experiments for the first product
2021
Apr
GMP facility construction
Aug
Acquired Sichuan Chengyu Biopharmaceutical, Ltd., focusing on vaccine developments
2023
Jan
First pipeline product in IND application stage
We are looking for business and academic partners globally to jointly develop new technologies and products, and promote industrial development.
If you are interested in collaborating, please send an email to: liudun@oncocare.com.cn
Europe
Academic environment conducive to innovative therapeutic research makes Europe a prime candidate for research partnership to make incremental product improvements and build global positioning as a thought leader.
China
Lower cost structures and less restrictive animal research regulations make China the best place to focus R&D and manufacturing capabilities.
United States
Favorable business climate (distribution networks, high margin pricing) and clinical regulatory environment make the US the best place to commercialize and build revenue.
a
n
c
o
c
a
r
e
